Bicitra

Drug Overview

Maintaining the delicate chemical balance of the body is a critical foundation of overall health. Within the specific Drug Category of Urology and nephrology, managing the acidity of the blood and urine is essential for treating and preventing painful conditions. The medication known commercially as Bicitra represents a highly effective, non-surgical intervention designed to manipulate this chemical environment safely.

Bicitra belongs to a specialized Drug Class known as Urinary Alkalinizers. Unlike pain medications that simply mask the symptoms of a kidney stone, or muscle relaxants that help a stone pass, this medication actively changes the chemistry of the urinary tract. By neutralizing excess acid, it helps dissolve existing stones, prevents new ones from forming, and protects the kidneys from severe metabolic imbalances.

• Generic Name: Sodium citrate and citric acid
• US Brand Names: Bicitra, Shohl’s Solution
• Route of Administration: Oral liquid solution
• FDA Approval Status: Fully FDA-approved for the management of chronic metabolic acidosis and conditions where long-term maintenance of alkaline urine is desirable.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Bicitra works, one must look at the way the kidneys filter waste and maintain the body’s pH balance. The human body naturally produces acids during daily metabolic processes. When the kidneys fail to excrete this acid, or when a patient suffers from chronic diarrhea, the blood becomes dangerously acidic (metabolic acidosis). Furthermore, highly acidic urine creates the perfect environment for uric acid and calcium oxalate to crystallize into solid kidney stones.

Bicitra functions through systemic and urinary alkalinization. When the oral solution is swallowed and absorbed into the bloodstream, the sodium citrate is transported to the liver. In the liver, the citrate is metabolized into sodium bicarbonate. Bicarbonate is a powerful, natural alkaline (base) buffer. As this bicarbonate enters the bloodstream, it actively neutralizes excess acid, safely raising the blood pH back to normal physiological levels.

Subsequently, the kidneys filter this excess bicarbonate and un-metabolized citrate into the urine. This has a dual physiological effect. First, it raises the urine pH, making it less acidic, which literally dissolves uric acid and cystine stones. Second, the citrate in the urine acts as a powerful chelating agent. It actively binds to free-floating calcium in the urine. By binding to the calcium, the citrate prevents the calcium from attaching to oxalate or phosphate, effectively halting the molecular crystallization process that forms solid kidney stones.

FDA-Approved Clinical Indications

Primary Indication

• Metabolic Acidosis and Kidney Stone Prevention: Bicitra is specifically FDA-approved to treat metabolic acidosis, a condition where the blood becomes too acidic due to kidney impairment. Concurrently, it is a primary treatment for the prevention and dissolution of uric acid calculi (kidney stones) and the prevention of calcium oxalate stones by making the urine more alkaline.

Other Approved & Off-Label Uses

While Bicitra is foundational for stone management, urologists utilize its alkalinizing properties for other conditions that cause chronic pelvic pain and urinary distress:

• Primary Urology Indications:
  • Interstitial Cystitis (IC): Used off-label to raise the pH of the urine, making it less acidic and thereby reducing the severe burning and bladder irritation associated with IC and painful bladder syndrome.
  • Gout-Related Nephropathy: Used to flush excess uric acid from the kidneys in patients suffering from severe gout, preventing the acid from damaging delicate renal tissues.
  • Urinary Tract Infections (UTIs): Occasionally used temporarily to neutralize urine acidity, which can help relieve the burning sensation during active urinary infections.

Dosage and Administration Protocols

Proper dosing of Bicitra is highly dependent on the patient’s baseline kidney function and the specific condition being treated. The medication is a highly concentrated, sour liquid that must be diluted.

Special Populations and Adjustments:

• Renal Insufficiency: Severe dose adjustments or complete avoidance may be required for patients with severe renal insufficiency (CrCl/GFR < 30 mL/min). Because Bicitra contains high levels of sodium, kidneys that are failing cannot excrete the excess sodium, leading to dangerous fluid overload.
• Administration Timing: The medication must be taken strictly after meals to avoid a laxative effect and severe stomach cramping.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

The clinical efficacy of urinary alkalinizers is heavily supported by ongoing urological and nephrological research. Current clinical study data (2020-2026) validates that maintaining a urinary pH between 6.5 and 7.0 using citrate therapy can effectively dissolve uric acid stones at a rate of approximately 1 centimeter of stone volume per month.

Furthermore, in patients with a history of recurrent calcium oxalate stones, long-term adherence to Bicitra reduces the recurrence rate by up to 80%. This profound reduction in stone formation directly decreases the need for repeated emergency room visits and surgical interventions.

In the realm of uro-oncology, maintaining healthy kidney filtration is critical. For patients undergoing aggressive cancer treatments, including advanced Targeted Therapy or systemic Immunotherapy for Renal Cell Carcinoma, preventing the formation of uric acid stones (often caused by the rapid breakdown of tumor cells) protects the remaining healthy kidney tissue and ensures the patient can safely continue their life-saving oncology protocols.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Bicitra. However, strict precautions apply to patients with cardiovascular conditions.

Common Side Effects (>10%)

• Gastrointestinal Distress: Nausea, vomiting, and diarrhea are very common, primarily due to the drug’s hyperosmolar (highly concentrated) nature pulling water into the intestines.
• Stomach Cramping: Often occurs if the medication is taken on an empty stomach or without adequate dilution.

Serious Adverse Events

• Hypernatremia (High Sodium): Because Bicitra is a sodium-based salt, it can cause a dangerous buildup of sodium in the blood.
• Fluid Retention and Edema: The high sodium load can exacerbate high blood pressure, heart failure, and acute kidney injury by causing the body to retain massive amounts of water.
• Metabolic Alkalosis: Over-treatment can cause the blood to become too alkaline, leading to muscle twitching, spasms, and severe metabolic imbalances.

Management Strategies

Healthcare providers manage the gastrointestinal side effects by instructing patients to dilute the liquid in a full glass of water or juice, and to sip it slowly after a large meal. Routine monitoring of blood pressure is strictly required for patients with pre-existing cardiovascular risks to ensure the sodium load is not causing fluid retention.

Research Areas

Current urological research is exploring how chemical alkalinization can be integrated seamlessly with modern surgical techniques. Following robotic-assisted surgery or minimally invasive procedures for large kidney stones (such as percutaneous nephrolithotomy), microscopic stone fragments often remain. Active clinical trials are investigating the use of Bicitra immediately post-surgery to chemically dissolve these residual “dust” particles before they can grow into new stones. Additionally, pharmaceutical researchers are actively developing long-acting, extended-release citrate capsules to replace the sour-tasting liquid, aiming to drastically improve long-term patient compliance.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A 24-hour urine collection test is mandatory to measure baseline levels of calcium, oxalate, uric acid, and citrate. A standard Urinalysis provides the baseline urinary pH.
• Organ Function: A comprehensive metabolic panel to check Renal function (BUN/Creatinine) and serum electrolytes (sodium, potassium, bicarbonate) is required before initiating therapy.
• Screening: Cardiovascular health must be carefully screened. Patients with a history of congestive heart failure or severe hypertension must be evaluated for their ability to handle the extra sodium.

Monitoring and Precautions

• Vigilance: Patients are often given at-home pH testing strips to monitor their morning urine. The physician will adjust the dose based on these daily readings to ensure the pH stays in the safe target zone (usually 6.5 to 7.0).
• Lifestyle: Patients must practice aggressive fluid management, aiming to drink at least 2.5 to 3 liters of water daily to keep the urine physically diluted. Dietary triggers, such as high-salt foods and purine-rich meats (which produce uric acid), must be strictly avoided.

“Do’s and Don’ts” List

• DO dilute the liquid medication in at least 4 to 6 ounces of water or juice before drinking it.
• DO take the medication immediately after meals to prevent stomach upset and diarrhea.
• DO use the at-home urine pH strips exactly as your urologist instructs.
• DON’T take Bicitra on an empty stomach.
• DON’T add extra table salt to your food, as this medication already contains a significant amount of sodium.
• DON’T take aluminum-based antacids while on this medication, as citrate can cause your body to absorb toxic levels of aluminum.

Legal Disclaimer

The information provided in this medical guide is for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider, nephrologist, or specialist Urologist regarding any medical conditions, dietary changes, treatment protocols, or specific medication interactions. Never disregard professional medical advice or delay in seeking it because of something you have read in this material.